Search results for " myeloid"

showing 10 items of 234 documents

Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib

2020

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by neoplastic transformation of pluripotent cells due to a typical cytogenetic and molecular mutation known as Philadelphia (Ph) chromosome. In 2001, the introduction of the tyrosine kinasis inhibitor (TKI) imatinib as a therapeutic strategy for CML with PH chromosome mutation represented an important step towards treatment of these patients, and nowadays, this drug represents the gold therapeutic standard in this clinical setting. A second generation of TKIs (dasatinib, nilotinib, and bosutinib) showed an effective action in all patients with mutations resistant to imatinib. Ponatinib is a third-generation TKI an…

Oncologymedicine.medical_specialtyTyrosine kinase inhibitorReview030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicinemedicineHumansNeoplastic transformation030212 general & internal medicineProtein Kinase InhibitorsTyrosine kinase inhibitorsCardiotoxicitybusiness.industryPonatinibChronic myeloid leukemiaImidazolesDisease ManagementMyeloid leukemiaImatinibPyridazinesDasatinibCardio-oncologyEarly DiagnosisNilotinibchemistryCardiovascular DiseasesPonatinibPonatinib . Tyrosine kinase inhibitors . Chronic myeloid leukemia . Cardio-oncology . ReviewCardiology and Cardiovascular MedicinebusinessBosutinibFollow-Up Studiesmedicine.drug
researchProduct

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

2021

Chronic myeloid leukemia; BCR-ABL1 transcripts; Response to imatinib Leucemia mieloide crónica; Transcripciones de BCR-ABL1; Respuesta al imatinib Leucèmia mieloide crònica; Transcripcions BCR-ABL1; Resposta a imatinib The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response …

Oncologymedicine.medical_specialtyrelapse-free survivalLeucèmia mieloide<i>BCR</i><i>-ABL1</i> transcriptsLeucèmia mieloide crònica:Organic Chemicals::Amides::Benzamides::Imatinib Mesylate [CHEMICALS AND DRUGS]survivalArticleOncología:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myelogenous Chronic BCR-ABL Positive [DISEASES]03 medical and health sciencesBcr abl10302 clinical medicineAnàlisi de supervivència (Biometria)chronic myeloid leukemiaInternal medicinehemic and lymphatic diseasesresponse to imatinibmedicineOverall survivalHematologíaCumulative incidenceBCR-ABL1 transcriptsGene transcriptbusiness.industryRMyeloid leukemiaImatinibGeneral MedicineExpressió gènica:técnicas de investigación::métodos epidemiológicos::estadística como asunto::análisis de supervivencia [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Myeloid leukemia030220 oncology & carcinogenesisMolecular ResponseImatinib:compuestos orgánicos::amidas::benzamidas::mesilato de imatinib [COMPUESTOS QUÍMICOS Y DROGAS]MedicineRemission rateGene expression:Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Survival Analysis [HEALTH CARE]business:neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mielogenosa crónica BCR-ABL positiva [ENFERMEDADES]030215 immunologymedicine.drugdiscontinuation
researchProduct

Bridge-Induced Translocation between NUP145 and TOP2 Yeast Genes Models the Genetic Fusion between the Human Orthologs Associated With Acute Myeloid …

2017

In mammalian organisms liquid tumors such as acute myeloid leukemia (AML) are related to spontaneous chromosomal translocations ensuing in gene fusions. We previously developed a system named bridge-induced translocation (BIT) that allows linking together two different chromosomes exploiting the strong endogenous homologous recombination system of the yeast Saccharomyces cerevisiae. The BIT system generates a heterogeneous population of cells with different aneuploidies and severe aberrant phenotypes reminiscent of a cancerogenic transformation. In this work, thanks to a complex pop-out methodology of the marker used for the selection of translocants, we succeeded by BIT technology to preci…

P53bridge-induced translocationgene fusionnucleoporinacute myeloid leukemiayeastlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282Frontiers in Oncology
researchProduct

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

2017

Abstract The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for …

PathologyNeoplasm ResidualInternational CooperationDiseaseReview ArticleBiochemistryEuropean LeukemiaNet0302 clinical medicineRisk Factorshemic and lymphatic diseasesCONVENTIONAL CARE REGIMENSDisease management (health)medicine.diagnostic_testACUTE MYELOGENOUS LEUKEMIAHematopoietic Stem Cell TransplantationDisease ManagementSINGLE CEBPA MUTATIONSHematology1ST COMPLETE REMISSIONHIGH-DOSE CYTARABINELeukemia Myeloid AcuteTreatment Outcome030220 oncology & carcinogenesisPractice Guidelines as TopicAdultmedicine.medical_specialtyConsensusImmunologyBUSULFAN PLUS CYCLOPHOSPHAMIDEMEDLINEMINIMAL RESIDUAL DISEASEAntineoplastic AgentsACUTE MYELOID-LEUKEMIAEnasidenibTransplantation AutologousDrug Administration ScheduleImmunophenotyping03 medical and health sciencesmedicineHumansGenetic TestingIntensive care medicineGenetic testingbusiness.industrySTEM-CELL TRANSPLANTATIONCell BiologyRANDOMIZED PHASE-IIIMinimal residual diseaseTransplantationbusinessSettore MED/15 - Malattie del Sangue030215 immunology
researchProduct

Transfusion-associated graft-versus-host disease-report of two further cases with an immunohistochemical analysis

1994

Summary Transfusion-associated graft-vs.-host disease (tGVHD) is a severe disease usually affecting immunocompromised hosts with haematological neoplasia. Two patients with acute leukaemia are reported, who developed fatal tGVHD after blood transfusions. Intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and endothelial leucocyte adhesion molecule 1 (ELAM-1) expression and the CD4/CD8 ratio were assessed in lesional skin. ICAM-1 was strongly expressed on epidermal keratinocytes and endothelial cells (EC) and correlated with HLA-DR staining. VCAM-1 was strongly expressed on EC in the superficial dermal vessels. ELAM-1 stained weakly on EC in some of the su…

Pathologymedicine.medical_specialtyBlood transfusionCD3medicine.medical_treatmentIntercellular Adhesion Molecule-1CD4-CD8 RatioGraft vs Host DiseaseVascular Cell Adhesion Molecule-1CD18DermatologyTransfusion-associated graft versus host diseaseFatal OutcomeHumansLeukemia-Lymphoma Adult T-CellMedicineSkinbiologybusiness.industryCell adhesion moleculeTransfusion ReactionMiddle AgedIntercellular Adhesion Molecule-1medicine.diseaseLeukemia Myeloid AcuteLeukemiaImmunologybiology.proteinFemalebusinessCell Adhesion MoleculesCD8Clinical and Experimental Dermatology
researchProduct

Granulocytic sarcoma of the oral cavity in a chronic myeloid leukemia patient : an unusual presentation

2009

Intraoral granulocytic sarcoma is an unusual manifestation of chronic or acute leukemia. The oral manifestations often involve enlargements of the gingival and mucosal tissue from direct leukemic cell infiltration. Only 38 cases have been reported in scientific literature to date. We present the case of a 47 year-old female who was diagnosed with chronic myeloid leukemia (CML) in December 2006. She was referred to a dentist for further evaluation, revealing generalized gingival overgrowth as well as periodontal, apical disease, and bleeding of the gums. An oral biopsy was performed and histological features revealed immature blast-like cells.

Pathologymedicine.medical_specialtyDiseaseMyelogenousLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesBiopsyMedicineHumansSarcoma MyeloidGeneral DentistryAcute leukemiamedicine.diagnostic_testbusiness.industryMyeloid leukemiaMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]LeukemiaOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryFemaleMouth NeoplasmsSarcomabusinessInfiltration (medical)
researchProduct

The ins and outs of osteopontin.

2015

The continuous remodeling of progressing tumors demands non-physiologic production of extracellular matrix (ECM) proteins. Among them, osteopontin (OPN) has been largely involved in tumor progression and metastasis. We have recently discovered a new mechanism for OPN in the metastatic spread of mammary carcinoma providing local immunosuppression at the seeding site.

Pathologymedicine.medical_specialtybiologymedicine.medical_treatmentImmunologyImmunosuppressionMetastasimedicine.diseaseMetastasisMammary carcinomaExtracellular matrixOncologystomatognathic systemTumor progressionMyeloid-derived suppressor cellbiology.proteinCancer researchMyeloid-derived Suppressor CellmedicineImmunology and AllergyOsteopontinOsteopontinAuthor's ViewMetastasis; Myeloid-derived suppressor cells; Osteopontin; Immunology and Allergy; Oncology; ImmunologyOncoimmunology
researchProduct

Synthesis of 2H-Imidazo[2',1':2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myelo…

2022

Despite progressive advances in understanding the molecular biology of acute myeloid leukemia (AML), the conventional therapeutic approach has not changed substantially, and the outcome for most patients is poor. Thus, continuous efforts on the discovery of new compounds with improved features are required. Following a multistep sequence, we have identified a new tetracyclic ring system with strong antiproliferative activity towards several haematological cell lines. The new compounds possess structural properties typical of inactive-state-binding kinase inhibitors and are structurally related to quizartinib which is known as type-II tyrosine kinase inhibitor. In particular, the high activi…

PharmacologyFMS-like tyrosine kinase 3 (FLT3)FLT3/ITD3][13]thiazolo[4Organic Chemistry2H-imidazo [2′1':23][13]thiazolo[45-e]isoindol-8-yl-phenylureas2H-imidazo [2′1':23][13]thiazolo[45-e]isoindol-8-yl-phenylureas; Acute myeloid leukemia (AML); FLT3/ITD; FMS-like tyrosine kinase 3 (FLT3); Internal tandem duplication (ITD)ApoptosisGeneral Medicine2H-imidazo [2′Leukemia Myeloid AcuteMiceInternal tandem duplication (ITD)fms-Like Tyrosine Kinase 35-e]isoindol-8-yl-phenylureasCell Line TumorDrug DiscoveryMutationAcute myeloid leukemia (AML)AnimalsHumansProtein Kinase Inhibitors1':2European journal of medicinal chemistry
researchProduct

Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal.

1996

Induction of apoptosis by growth factor deprivation or gamma-irradiation-induced DNA damage was directly studied in proliferating primary haemopoietic cells derived from CD34-positive cells of 13 CML patients and 12 normal controls. CD34-positive cells were cultured in the presence of appropriate concentrations of SCF and G-CSF for 5–7 d. After gamma irradiation with 500 rad or growth factor deprivation, the fraction of apoptotic cells was assessed by two independent methods applying either measurement of cells incorporating FITC-labelled dUTP by terminal transferase or assessment of the fraction of cells with a less than 2N DNA content in flow cytometry. Proliferating CML cells were not re…

Programmed cell deathDNA damagemedicine.medical_treatmentFusion Proteins bcr-ablApoptosisBiologyFlow cytometrychemistry.chemical_compoundhemic and lymphatic diseasesGranulocyte Colony-Stimulating FactormedicineHumansStem Cell Factormedicine.diagnostic_testGrowth factorHematologyHematopoietic Stem CellsIn vitroTerminal deoxynucleotidyl transferasechemistryApoptosisGamma RaysImmunologyLeukemia Myeloid Chronic-PhaseCancer researchDNACell DivisionDNA DamageBritish journal of haematology
researchProduct

Factors affecting the amount and the mode of merocyanine 540 binding to the membrane of human erythrocytes. A comparison with the binding to leukemia…

1995

Abstract In the presence of albumin Merocyanine 540 (MC540) exhibits a very limited binding to the outer surface of the membrane of normal erythrocytes, whereas pronounced binding is observed to leukemia cells. To find out whether this difference is due to differences in the composition or structural organization of the cell membrane we analyzed effects of a number of covalent and non-covalent perturbations of the red cell membrane on the binding and fluorescence characteristics of membrane-bound MC540. It is shown that exposure of the cells to cationic chlorpromazine, neuraminidase or photodynamic treatment with AlPcS 4 as sensitizer caused a limited increase (30–50%) of MC540 binding, tog…

Radiation-Sensitizing AgentsTMA-DPHHot TemperatureIndolesBSALightChlorpromazineLipid BilayersBiophysicsPhospholipidNeuraminidaseQuantum yieldPyrimidinonesBiochemistryCell membranechemistry.chemical_compoundt-BuOOHOrganometallic CompoundsTumor Cells CulturedmedicineMerocyanine 540HumansPBSCell MembraneErythrocyte MembraneMembrane structureCell Biologymedicine.diseasePEGFluorescenceDIDSLeukemiaLeukemia cellAlPcS4CholesterolSpectrometry FluorescenceMembranemedicine.anatomical_structureBNML cellsBiochemistrychemistryLeukemia MyeloidCovalent bondBiophysicsMC540Biochimica et Biophysica Acta (BBA) - Biomembranes
researchProduct